The prognosis of high-risk retinoblastoma (RB) with extraocular disease, relapse, or invasion of the cut end of the optic nerve is extremely poor. Following the discontinuation of thiotepa production in Japan, BU-and melphalan (Mel)-based regimens have been used, followed by the standard treatment for neuroblastoma. This study retrospectively analyzed 14 high-risk RB patients who underwent high-dose chemotherapy (HDC) and hematopoietic SCT; 8 received a BU/Mel conditioning regimen and 6 received other regimens. The disease status at HDC was relapse in 8 patients and extraocular involvement in 5. All patients received peripheral blood stem cell infusion 41.5 × 10 6 /kg. Engraftment occurred within a median of 11 days (BU/Mel: 10-13, others: 9-13). Primary toxicities included mucositis (Xgrade 3) in 9 patients (4 with BU/Mel, 5 with others). Veno-occlusive disease (VOD) occurred in two 1-year-old patients in the BU/Mel group. There were no treatment-related deaths. Of 4 (2 with BU/Mel, 2 with others) patients with central nervous system (CNS) relapse after HDC, 3 died. In conclusion, the BU/Mel regimen may be feasible for high-risk RB under careful monitoring for VOD, particularly in younger patients. CNS relapse associated with a lethal prognosis occurred after all regimens; therefore, further evaluation of HDC efficacy for high-risk RB is required.
INTRODUCTION
The prognosis of high-risk retinoblastoma (RB) with extraocular disease, relapse or invasion of the cut end of the optic nerve is poor. 1 Following the discontinuation of thiotepa production in Japan, BU-and melphalan (Mel)-based regimens have been used. This study aimed to evaluate the clinical courses and outcomes of high-risk RB patients who underwent high-dose chemotherapy and SCT and to evaluate the feasibility of the BU/Mel regimen for these patients.
PATIENTS AND METHODS
This study is a retrospective chart review of 14 patients diagnosed with retinoblastoma (RB) who underwent high-dose chemotherapy (HDC) and SCT at the National Cancer Center Hospital (NCCH) between 2000 and 2013 ( Table 1 ). The study outcomes were clinical courses and patient prognoses. The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v4.0; The US Department of Health and Human Services) was used to grade treatment-related toxicity.
The median follow-up period from RB diagnosis was 47 months (range, 11-187 months). All patients underwent conventional chemotherapy before HDC ( Table 2 ). The PBSCs were harvested after recovery from the chemotherapy cycle and cryopreserved. Informed consent was obtained for these treatments and procedures from all parents and this study was performed with IRB approval. BM biopsies were performed before harvesting from patients with BM invasion; no tumor cells were observed by morphological analysis. The median age at SCT was 4 years (range, 1.7-8.5 years). The conditioning regimens included melphalan (Mel) 
CD34
+ cells/kg were thawed rapidly and infused~24 h after completion of conditioning chemotherapy. Concomitantly, G-CSF was administered daily until stable neutrophil engraftment was achieved.
RESULTS
In all patients, BM reconstitution was promptly achieved. Neutrophil engraftment occurred within a median of 11 days (range, 10-13 days with the BU/Mel regimen and 9-13 days with the other two regimens). Platelet engraftment after SCT occurred within a median of 16.5 days (range, 13-121 days) with the BU/Mel regimen and 21.5 days (range, 16-27 days) with the other two regimens.
The primary nonhematological toxicities (4grade 3) included mucositis in nine patients (BU/Mel, n = 4; other regimens, n = 5) and febrile neutropenia in six (BU/Mel, n = 3; other regimens, n = 3). Veno-occlusive disease (VOD) occurred in two patients in the BU/Mel group (day 19 and day 26); both patients were 1.7 years of age at HDC and SCT. Although the recovery of platelet counts was delayed (day 87 and day 121) in these patients, both were effectively treated with defibrotides.
After HDC and SCT, four patients developed CNS relapse (BU/ Mel, n = 2; thioetepa-containing regimen, n = 1; MEC regimen, n = 1). The durations between SCT and relapse were 6 and 15 months with the BU/Mel regimen, and 5 and 10 months with the other regimens. Three (BU/Mel, n = 1; thiotepa-containing regimen, n = 1; MEC regimen, n = 1) of the four patients died of CNS relapse at 6, 33 and 14 months, respectively, after SCT. There were no cases of secondary cancer. 
DISCUSSION
The effectiveness of HDC with SCT for high-risk RB without CNS involvement was previously reported. [2] [3] [4] [5] [6] [7] However, an appropriate single protocol of HDC has never been assessed. RB is known to respond well to alkylating agents, and Mel is one of the key drugs in this regard. Since the discontinuation of thiotepa production in Japan in 2009, MEC 8 or BU/Mel regimens have been used, referring to the standard treatment for neuroblastoma. In 2011, the BU/Mel regimen was shown to be superior to MEC for highrisk neuroblastoma, both BU and Mel have good CNS penetration, supporting the use of this regimen for high-risk RB after 2011. 9, 10 To our knowledge, this is the first report that examined the BU/Mel regimen for high-risk RB. It is particularly worth noting that VOD (grade 3) occurred in two of three patients aged o 2 years who received the BU/Mel regimen, and it did not occur with any of the other regimens. For neuroblastoma patients who received the BU/Mel regimen, with a high frequency of associated VOD, particularly in infants. 11 We suggest a dose optimization of both BU and Mel for younger patients to prevent VOD. Because of the small sample size, we did not perform statistical analysis, and there was no difference among groups in terms of in neutrophil engraftment and treatment-related toxicities. Although orbital or distant metastases after HDC and SCT are relatively rare, CNS relapse could not be prevented after SCT and HDC with any of the regimens including chemotherapeutic agents known to have good CNS penetration. None of our patients developed local relapses or bone/BM metastases after HDC and SCT; however, CNS relapse occurred with an equal frequency with all regimens. These findings indicate that although the BU/Mel regimen may be as effective as thiotepa-containing and MEC regimens in preventing local relapse or distant metastases, further evaluation of its efficacy for preventing CNS relapse is required.
Our study faces many limitations. We did not compare the efficacy of these regimens because of the small sample size and this study included both regional disease (post-enucleation positive optic nerve margin) that might be cured without HDC and distant metastatic disease.
In conclusion, the BU/Mel regimen may be feasible for high-risk RB patients under continuous monitoring for VOD, particularly in younger patients. Because CNS relapse could not be prevented with any of the HDC regimens and were mostly associated with a lethal prognosis, further evaluation of HDC efficacy and the development of new promising therapeutic strategies are required.
